Biogen Idec (NASDAQ:BIIB) missed analyst expectations last quarter, but will try to make up for it when it announces its latest results on Tuesday.
Analysts currently expect Biogen Idec to come in with earnings of $1.56 per share on revenues of $1.33 billion. Estimates range from $1.49 per share to $1.60 per share. Over the past three months, the average estimate has moved up from $1.54.
The biggest recent change for the stock came on June 14, 2012, when it rose $4.44 per share to $138.66. Looking at change over the last three months, from April 23, 2012 and July 18, 2012, the stock price is up $19.11 (15.2%), from $125.85 to $144.96.
Company Fundamental Trends
Analysts are bullish on the stock as 12 analysts rate it as a buy and there are no sell ratings. Analyst sentiment has been improving recently, as the average rating risen slightly over the past three months.
Last Quarter's Results
In the first quarter, profit rose 2.8% to $302.7 million ($1.25 a share) from $294.3 million ($1.20 a share) the year earlier, but fell short analyst expectations. Revenue rose 7.4% to $1.29 billion from $1.2 billion.
Reporting Period: 2Q
Date of Release: Tuesday, July 24, 2012 before market open
Revenue Estimate: $1.33 billion
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)